Immune Modulation as a Treatment for Abdominal Aortic Aneurysms

S. Keisin Wang, Michael P. Murphy

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.

Original languageEnglish (US)
Pages (from-to)925-927
Number of pages3
JournalCirculation research
Issue number7
StatePublished - Mar 30 2018


  • angiotensin II
  • aortic aneurysm, abdominal
  • doxycycline
  • matrix metalloproteinases
  • risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Immune Modulation as a Treatment for Abdominal Aortic Aneurysms'. Together they form a unique fingerprint.

Cite this